Cargando…

Delivery of miR-200c-3p Using Tumor-Targeted Mesoporous Silica Nanoparticles for Breast Cancer Therapy

[Image: see text] Despite advances in breast cancer treatment, it remains the leading cause of cancer-related death in women worldwide. In this context, microRNAs have emerged as potential therapeutic targets but still present some limitations for in vivo applications. Particularly, miR-200c-3p is a...

Descripción completa

Detalles Bibliográficos
Autores principales: Garrido-Cano, Iris, Adam-Artigues, Anna, Lameirinhas, Ana, Blandez, Juan F., Candela-Noguera, Vicente, Lluch, Ana, Bermejo, Begoña, Sancenón, Felix, Cejalvo, Juan Miguel, Martínez-Máñez, Ramón, Eroles, Pilar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2023
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10436244/
https://www.ncbi.nlm.nih.gov/pubmed/37549382
http://dx.doi.org/10.1021/acsami.3c07541
_version_ 1785092279741972480
author Garrido-Cano, Iris
Adam-Artigues, Anna
Lameirinhas, Ana
Blandez, Juan F.
Candela-Noguera, Vicente
Lluch, Ana
Bermejo, Begoña
Sancenón, Felix
Cejalvo, Juan Miguel
Martínez-Máñez, Ramón
Eroles, Pilar
author_facet Garrido-Cano, Iris
Adam-Artigues, Anna
Lameirinhas, Ana
Blandez, Juan F.
Candela-Noguera, Vicente
Lluch, Ana
Bermejo, Begoña
Sancenón, Felix
Cejalvo, Juan Miguel
Martínez-Máñez, Ramón
Eroles, Pilar
author_sort Garrido-Cano, Iris
collection PubMed
description [Image: see text] Despite advances in breast cancer treatment, it remains the leading cause of cancer-related death in women worldwide. In this context, microRNAs have emerged as potential therapeutic targets but still present some limitations for in vivo applications. Particularly, miR-200c-3p is a well-known tumor suppressor microRNA that inhibits tumor progression and metastasis in breast cancer through downregulating ZEB1 and ZEB2. Based on the above, we describe the design and validation of a nanodevice using mesoporous silica nanoparticles for miR-200c-3p delivery for breast cancer treatment. We demonstrate the biocompatibility of the synthesized nanodevices as well as their ability to escape from endosomes/lysosomes and inhibit tumorigenesis, invasion, migration, and proliferation of tumor cells in vitro. Moreover, tumor targeting and effective delivery of miR-200c-3p from the nanoparticles in vivo are confirmed in an orthotopic breast cancer mouse model, and the therapeutic efficacy is also evidenced by a decrease in tumor size and lung metastasis, while showing no signs of toxicity. Overall, our results provide evidence that miR-200c-3p-loaded nanoparticles are a potential strategy for breast cancer therapy and a safe and effective system for tumor-targeted delivery of microRNAs.
format Online
Article
Text
id pubmed-10436244
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-104362442023-08-19 Delivery of miR-200c-3p Using Tumor-Targeted Mesoporous Silica Nanoparticles for Breast Cancer Therapy Garrido-Cano, Iris Adam-Artigues, Anna Lameirinhas, Ana Blandez, Juan F. Candela-Noguera, Vicente Lluch, Ana Bermejo, Begoña Sancenón, Felix Cejalvo, Juan Miguel Martínez-Máñez, Ramón Eroles, Pilar ACS Appl Mater Interfaces [Image: see text] Despite advances in breast cancer treatment, it remains the leading cause of cancer-related death in women worldwide. In this context, microRNAs have emerged as potential therapeutic targets but still present some limitations for in vivo applications. Particularly, miR-200c-3p is a well-known tumor suppressor microRNA that inhibits tumor progression and metastasis in breast cancer through downregulating ZEB1 and ZEB2. Based on the above, we describe the design and validation of a nanodevice using mesoporous silica nanoparticles for miR-200c-3p delivery for breast cancer treatment. We demonstrate the biocompatibility of the synthesized nanodevices as well as their ability to escape from endosomes/lysosomes and inhibit tumorigenesis, invasion, migration, and proliferation of tumor cells in vitro. Moreover, tumor targeting and effective delivery of miR-200c-3p from the nanoparticles in vivo are confirmed in an orthotopic breast cancer mouse model, and the therapeutic efficacy is also evidenced by a decrease in tumor size and lung metastasis, while showing no signs of toxicity. Overall, our results provide evidence that miR-200c-3p-loaded nanoparticles are a potential strategy for breast cancer therapy and a safe and effective system for tumor-targeted delivery of microRNAs. American Chemical Society 2023-08-07 /pmc/articles/PMC10436244/ /pubmed/37549382 http://dx.doi.org/10.1021/acsami.3c07541 Text en © 2023 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by/4.0/Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Garrido-Cano, Iris
Adam-Artigues, Anna
Lameirinhas, Ana
Blandez, Juan F.
Candela-Noguera, Vicente
Lluch, Ana
Bermejo, Begoña
Sancenón, Felix
Cejalvo, Juan Miguel
Martínez-Máñez, Ramón
Eroles, Pilar
Delivery of miR-200c-3p Using Tumor-Targeted Mesoporous Silica Nanoparticles for Breast Cancer Therapy
title Delivery of miR-200c-3p Using Tumor-Targeted Mesoporous Silica Nanoparticles for Breast Cancer Therapy
title_full Delivery of miR-200c-3p Using Tumor-Targeted Mesoporous Silica Nanoparticles for Breast Cancer Therapy
title_fullStr Delivery of miR-200c-3p Using Tumor-Targeted Mesoporous Silica Nanoparticles for Breast Cancer Therapy
title_full_unstemmed Delivery of miR-200c-3p Using Tumor-Targeted Mesoporous Silica Nanoparticles for Breast Cancer Therapy
title_short Delivery of miR-200c-3p Using Tumor-Targeted Mesoporous Silica Nanoparticles for Breast Cancer Therapy
title_sort delivery of mir-200c-3p using tumor-targeted mesoporous silica nanoparticles for breast cancer therapy
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10436244/
https://www.ncbi.nlm.nih.gov/pubmed/37549382
http://dx.doi.org/10.1021/acsami.3c07541
work_keys_str_mv AT garridocanoiris deliveryofmir200c3pusingtumortargetedmesoporoussilicananoparticlesforbreastcancertherapy
AT adamartiguesanna deliveryofmir200c3pusingtumortargetedmesoporoussilicananoparticlesforbreastcancertherapy
AT lameirinhasana deliveryofmir200c3pusingtumortargetedmesoporoussilicananoparticlesforbreastcancertherapy
AT blandezjuanf deliveryofmir200c3pusingtumortargetedmesoporoussilicananoparticlesforbreastcancertherapy
AT candelanogueravicente deliveryofmir200c3pusingtumortargetedmesoporoussilicananoparticlesforbreastcancertherapy
AT lluchana deliveryofmir200c3pusingtumortargetedmesoporoussilicananoparticlesforbreastcancertherapy
AT bermejobegona deliveryofmir200c3pusingtumortargetedmesoporoussilicananoparticlesforbreastcancertherapy
AT sancenonfelix deliveryofmir200c3pusingtumortargetedmesoporoussilicananoparticlesforbreastcancertherapy
AT cejalvojuanmiguel deliveryofmir200c3pusingtumortargetedmesoporoussilicananoparticlesforbreastcancertherapy
AT martinezmanezramon deliveryofmir200c3pusingtumortargetedmesoporoussilicananoparticlesforbreastcancertherapy
AT erolespilar deliveryofmir200c3pusingtumortargetedmesoporoussilicananoparticlesforbreastcancertherapy